Upgrade to SI Premium - Free Trial

Nektar Therapeutics (NKTR)

59.31 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/7/26 *Est.)

Latest Headlines

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 3, 2026 4:15 PM - PR NewsWire Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York May 27, 2026 6:16 PM - PR NewsWire Form 3 NEKTAR THERAPEUTICS For: May 15 Filed by: Rubinstein Linda M May 26, 2026 6:20 PM - SEC Filing Form 4 NEKTAR THERAPEUTICS For: May 19 Filed by: Zalevsky Jonathan May 21, 2026 6:27 PM - SEC Filing Form 4 NEKTAR THERAPEUTICS For: May 19 Filed by: ROBIN HOWARD W May 21, 2026 6:26 PM - SEC Filing Form 144 NEKTAR THERAPEUTICS Filed by: Zalevsky Jonathan May 19, 2026 3:28 PM - SEC Filing Form 144 NEKTAR THERAPEUTICS Filed by: ROBIN HOWARD W May 19, 2026 3:25 PM - SEC Filing Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: BIOTECHNOLOGY VALUE FUND L P May 15, 2026 4:19 PM - SEC Filing Form 424B5 NEKTAR THERAPEUTICS May 8, 2026 5:23 PM - SEC Filing Form 8-K NEKTAR THERAPEUTICS For: May 08 May 8, 2026 5:11 PM - SEC Filing Nektar Therapeutics (NKTR ) PT Raised to $192 at Piper Sandler May 8, 2026 7:58 AM - StreetInsider Form 10-Q NEKTAR THERAPEUTICS For: Mar 31 May 8, 2026 6:03 AM - SEC Filing Nektar Therapeutics (NKTR) Misses Q1 EPS by 182c May 7, 2026 4:38 PM - StreetInsider Form 8-K NEKTAR THERAPEUTICS For: May 07 May 7, 2026 4:33 PM - SEC Filing Nektar Therapeutics Reports First Quarter 2026 Financial Results May 7, 2026 4:15 PM - PR NewsWire Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: FMR LLC May 6, 2026 11:31 AM - SEC Filing Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026 4:40 PM - PR NewsWire Nektar Therapeutics (NKTR) call put ratio 1 call to 3.8 puts with a focus on May puts April 29, 2026 2:54 PM - StreetInsider Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets April 28, 2026 6:00 PM - PR NewsWire Form ARS NEKTAR THERAPEUTICS For: Dec 31 April 24, 2026 4:19 PM - SEC Filing Form DEFA14A NEKTAR THERAPEUTICS April 24, 2026 4:18 PM - SEC Filing Form DEF 14A NEKTAR THERAPEUTICS For: Jun 04 April 24, 2026 4:16 PM - SEC Filing Nektar Therapeutics completes $373.8 million stock offering April 23, 2026 4:15 PM - StreetInsider Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares April 23, 2026 4:15 PM - PR NewsWire Form 8-K NEKTAR THERAPEUTICS For: Apr 21 April 23, 2026 6:06 AM - SEC Filing Form 424B5 NEKTAR THERAPEUTICS April 23, 2026 6:05 AM - SEC Filing Nektar Therapeutics (NKTR) PT Raised to $150 at Jefferies April 22, 2026 12:21 PM - StreetInsider Nektar prices upsized $325 million public offering at $92 per share April 21, 2026 9:30 PM - StreetInsider Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering April 21, 2026 9:30 PM - PR NewsWire Nektar Therapeutics (NKTR) PT Raised to $151 at Citi April 21, 2026 3:48 AM - StreetInsider Form 424B5 NEKTAR THERAPEUTICS April 20, 2026 5:01 PM - SEC Filing Form 8-K NEKTAR THERAPEUTICS For: Apr 20 April 20, 2026 4:59 PM - SEC Filing Nektar Therapeutics launches $250 million public offering April 20, 2026 4:01 PM - StreetInsider Nektar Therapeutics Announces Proposed Public Offering April 20, 2026 4:01 PM - PR NewsWire Nektar Therapeutics (NKTR) PT Raised to $95 at Wedbush April 20, 2026 10:57 AM - StreetInsider Nektar Therapeutics (NKTR) PT Raised to $185 at H.C. Wainwright April 20, 2026 10:35 AM - StreetInsider Nektar Therapeutics (NKTR) PT Raised to $178 at BTIG April 20, 2026 10:21 AM - StreetInsider Jefferies stays Buy on Nektar Therapeutics (NKTR) after Rezpeg data hits upside estimates, sees 10-30% stock move into Ph3 April 20, 2026 9:48 AM - StreetInsider Oppenheimer Reiterates Outperform Rating on Nektar Therapeutics (NKTR) April 20, 2026 8:23 AM - StreetInsider Form 8-K NEKTAR THERAPEUTICS For: Apr 20 April 20, 2026 8:02 AM - SEC Filing Nektar Therapeutics reports positive 52-week data for alopecia areata drug trial April 20, 2026 7:30 AM - StreetInsider Nektar Therapeutics (NKTR) Halted, News Pending April 20, 2026 7:30 AM - StreetInsider 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin April 20, 2026 7:30 AM - PR NewsWire Nektar Therapeutics to discuss alopecia areata trial results April 19, 2026 12:00 PM - StreetInsider Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 202 April 19, 2026 12:00 PM - PR NewsWire Form SCHEDULE 13G NEKTAR THERAPEUTICS Filed by: Two Seas Capital LP April 17, 2026 9:01 AM - SEC Filing Bernstein on US Pharma and Biotech: Who might buy whom? April 13, 2026 5:52 AM - StreetInsider Citi Adds Nektar Therapeutics (NKTR) to 30-Day Upside Catalyst Watch List April 7, 2026 8:36 AM - StreetInsider Oppenheimer on Nektar Therapeutics (NKTR): 'meaningful opportunities for biologics in AA' April 1, 2026 9:57 AM - StreetInsider Nektar presents rezpegaldesleukin data at dermatology meeting March 28, 2026 12:36 PM - StreetInsider Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting March 28, 2026 12:36 PM - PR NewsWire Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: VANGUARD GROUP INC March 27, 2026 10:49 AM - SEC Filing Wedbush Starts Nektar Therapeutics (NKTR) at Neutral March 24, 2026 6:53 AM - StreetInsider Nektar gets two presentations at dermatology meeting for drug trials March 20, 2026 10:00 AM - StreetInsider Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting March 20, 2026 10:00 AM - PR NewsWire DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions March 19, 2026 1:28 PM - Globe NewsWire DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders March 19, 2026 12:08 PM - Globe NewsWire Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors March 19, 2026 9:01 AM - Globe NewsWire NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm March 17, 2026 9:01 AM - PR NewsWire TD Cowen Starts Nektar Therapeutics (NKTR) at Buy March 17, 2026 5:30 AM - StreetInsider Nektar Therapeutics (NKTR) PT Raised to $123 at Citi March 16, 2026 5:41 AM - StreetInsider Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR March 16, 2026 3:09 AM - PR NewsWire Form 144 NEKTAR THERAPEUTICS Filed by: Wilson Mark Andrew March 13, 2026 1:05 PM - SEC Filing Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer March 13, 2026 12:39 PM - StreetInsider DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders March 13, 2026 12:08 PM - Globe NewsWire Form 10-K NEKTAR THERAPEUTICS For: Dec 31 March 13, 2026 6:05 AM - SEC Filing Form 8-K NEKTAR THERAPEUTICS For: Mar 12 March 12, 2026 4:45 PM - SEC Filing Nektar Therapeutics (NKTR) Misses Q4 EPS by 178c March 12, 2026 4:36 PM - StreetInsider Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results March 12, 2026 4:15 PM - PR NewsWire Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. March 10, 2026 9:08 AM - Globe NewsWire Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors March 10, 2026 9:01 AM - Globe NewsWire Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR) March 9, 2026 12:38 PM - Globe NewsWire Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR) March 9, 2026 7:12 AM - StreetInsider Full Article List